Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal Phase 3 trial
https://pubmed.ncbi.nlm.nih.gov/33549192/
Bimekizumab therapy was associated with a rapid and sustained improvement in PASI response and IGA score in patients with moderate to severe plaque psoriasis. Dual inhibition of IL-17A/F with bimekizumab can affect a more durable response in PsO patients than sole IL-17A inhibition. Gordon et al. compared the safety and efficacy of two different maintenance dosing schedules, in addition to the effects of treatment withdrawal in the 52-week BE READY trial.
Both bimekizumab Q4W and Q8W maintenance dosing schedules showed similar efficacy over 56 weeks. AEs were also predominantly mild and in line with the expected safety profile of bimekizumab.
Keywords:
